News | November 01, 2022
Aptar Pharma completes Phase I global injectables expansion program
The expansion program includes investments in France and the U.S., adding an additional 23,000+ m² of manufacturing footprint.
The expansion program includes investments in France and the U.S., adding an additional 23,000+ m² of manufacturing footprint.
This is the first injectable product approval from our General Sterile Facility (F-3) which was inspected in August, 2022.
Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr
Esiloc was launched at the biggest doctor engagement webinar involving more than 12,000 doctors across the country
None of the observations are related to data integrity and Alembic Pharmaceuticals management believes that they are addressable
He is a seasoned business leader with a successful track record of over 26 years across local and area roles within the pharmaceutical industry
Both the partners will work towards bringing Aster Pharmacy’s in-house quality care products to serve the healthcare needs of the local population in KSA
For the last ten financial years, the company has posted healthy performance with its revenue from operations growing at 15% CAGR and net profit at 23% CAGR
Since FY 2020 till FY 2022, the organisation has reduced energy consumption by 9.2%
Agreement strengthens Evonik’s track record as leading contract development and manufacturing organization (CDMO)
Subscribe To Our Newsletter & Stay Updated
